Product Description
an allosteric, palm site inhibitor of the HCV NS5B replicase (Sourced from: https://pubs.acs.org/doi/10.1021/acs.oprd.0c00198#)
Mechanisms of Action: HCV-NS5B Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatitis C, Chronic|Hepatitis A|Hepatitis C
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AI457-002 | P1 |
Withdrawn |
Hepatitis A|Hepatitis C, Chronic |
2013-02-01 |
2019-03-19 |
Treatments |
|
| ACTRN12611001038987 | P1 |
Not yet recruiting |
Hepatitis C |
None |
2024-04-03 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|